News

News
0 BioAgilytix acquires Cambridge Biomedical

BioAgilytix (NC, USA), a provider of large-molecule bioanalytical testing services, has announced the acquisition of the Boston-based CRO, Cambridge Biomedical (MA, USA), which also specializes in large-molecule bioanalysis.

News
0 Flotillin: a novel biomarker for Alzheimer’s disease?

Researchers have analyzed flotillin levels in samples from individuals with and without Alzheimer’s disease (AD) and determined that serum flotillin levels are negatively associated with brain amyloid deposition. Flotillin could serve as a biomarker to estimate brain amyloid deposition, potentially aiding the early diagnosis of AD.

1 2 3 110